BRAF and neoplasm: This may capture intratumoral transcriptomic heterogeneity in CRCs with more than one subtype signature coexisting in the same tumor and improve assessment of prognosis and its association with RAS/BRAF wild-type statuses and tumor sidedness in patients with mCRC treated with anti-EGFR therapy.10